<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05094986</url>
  </required_header>
  <id_info>
    <org_study_id>19/198-P</org_study_id>
    <nct_id>NCT05094986</nct_id>
  </id_info>
  <brief_title>Feasibility and Acceptability of a Complex Intervention to Improve Initial Medication Adherence</brief_title>
  <official_title>Pilot of a Complex Intervention to Improve Initial Medication Adherence to Cardiovascular and Diabetes Treatments in Primary Care</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundació Sant Joan de Déu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Parc Sanitari Sant Joan de Déu</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut Català de la Salut</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jordi Gol i Gurina Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Col·legi de Farmacèutics de la Província de Barcelona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CIBER of Epidemiology and Public Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundació Sant Joan de Déu</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot study aims to test the feasibility of the following effectiveness and&#xD;
      cost-effectiveness evaluation using Real-World Data.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A cluster non-randomised pilot study with an embedded process evaluation was carried out to&#xD;
      test the feasibility of the definitive cluster randomised controlled trial (cRCT). The cRCT&#xD;
      will aim to evaluate the effectiveness and cost-effectiveness of the Initial Medication&#xD;
      Adherence (IMA) intervention in comparison to usual care, to increase initiation of&#xD;
      pharmacological treatments for CVD and diabetes (antihypertensive drugs, hypolipidemic drugs,&#xD;
      antiplatelet drugs, and insulin and oral antidiabetics) prescribed in Primary Care (PC).&#xD;
&#xD;
      The pilot study was conducted in five PC centres (PCC) in Catalonia (Spain), two were&#xD;
      assigned to the control group and three to the intervention group. There were two target&#xD;
      participants, the implementation targeted professionals (general practitioners (GP), nurses,&#xD;
      and community pharmacists), and the population targeted by the intervention, PC patients.&#xD;
&#xD;
      The IMA intervention provided healthcare professionals with the knowledge, skills, and tools&#xD;
      to help the patient make an informed and shared decision with the GP to initiate a new CVD or&#xD;
      diabetes treatment. Professionals were trained on the problem of non-initiation,&#xD;
      communication skills, health literacy, and the use of decision aids (leaflets, website).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2020</start_date>
  <completion_date type="Actual">June 30, 2021</completion_date>
  <primary_completion_date type="Actual">January 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>PC patients: Patients from the intervention PCCs received the IMA intervention but were not aware of the group they were assigned to.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Overall quality of registries</measure>
    <time_frame>6 months after recruitment</time_frame>
    <description>Mean of the quality of clinical registries.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Active diagnosis registry</measure>
    <time_frame>6 months before and after recruitment</time_frame>
    <description>Proportion of patients with a new prescription of cardiovascular disease and diabetes treatments and an active diagnosis in the electronic system.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of clinical registries related to diabetes mellitus II</measure>
    <time_frame>6 months before and after recruitment</time_frame>
    <description>Rate of registries recorded six months before and after the prescription of:&#xD;
Glycated haemoglobin&#xD;
Glomerular filtrate&#xD;
Blood glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of clinical registries related to dyslipidemia</measure>
    <time_frame>6 months before and after recruitment</time_frame>
    <description>Rate of registries recorded six months before and after the prescription of:&#xD;
Total colesterol&#xD;
HDL cholesterol&#xD;
LDL colesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of clinical registries related to hypertension</measure>
    <time_frame>6 months before and after recruitment</time_frame>
    <description>Rate of registries recorded six months before and after the prescription of:&#xD;
Systolic blood pressure&#xD;
Diastolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of clinical registries related to cardiovascular risk</measure>
    <time_frame>6 months before and after recruitment</time_frame>
    <description>Rate of registries recorded six months before and after the prescription of:&#xD;
• REGICOR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Missing registries</measure>
    <time_frame>6 months before and after recruitment</time_frame>
    <description>Number of registries missing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Outliers registries</measure>
    <time_frame>6 months before and after recruitment</time_frame>
    <description>Number of registries with values out of their range.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">605</enrollment>
  <condition>Adherence, Medication</condition>
  <arm_group>
    <arm_group_label>Intervention group: IMA Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>General practitioners (GP) applied the IMA intervention to all patients receiving a new prescription for pharmacological treatments of cardiovascular disease or diabetes.&#xD;
Following the IMA intervention, nurses and community pharmacists offered information support in line with the information provided by the GP. Professionals had the intervention support tools available (leaflets, website and dispensing alert in community pharmacies).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthcare professionals from the control group prescribed medication and provided information as usual.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Initial Medication Adherence (IMA) Intervention</intervention_name>
    <description>The IMA intervention promotes health literacy and patient participation in the decision-making process during the recommendation and prescription of a new drug for the management of cardiovascular disease and diabetes. The IMA intervention has four main components: 1. Training for healthcare professionals (GPs, nurses, and community pharmacists) on non-initiation, shared-decision making, health literacy and use of decision aids; 2. Intervention support tools; decision aids (leaflets and website) and implementation tools (dispensing alert in community pharmacies when dispensing insulins and antiplatelet drugs); 3. Shared decision-making process during the GP's consultation; and 4. Information support provided by the nurses and community pharmacists that use the intervention decision aids to explore the patients' doubts and standardise the discourse between primary healthcare professionals.</description>
    <arm_group_label>Intervention group: IMA Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Usual Care</intervention_name>
    <description>Patients received the usual care when being prescribed a new prescription for treatments of cardiovascular disease or diabetes. Nurses and community pharmacists were asked to also provide usual care to those patients. Community pharmacists from the control group had the dispensing alert available when dispensing insulins and antiplatelet drugs.</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Primary healthcare professionals and pharmacists who:&#xD;
&#xD;
        • Agree to participate in the pilot study.&#xD;
&#xD;
        Primary care patients who:&#xD;
&#xD;
          -  Are prescribed a new treatment of cardiovascular disease o diabetes by a GP who&#xD;
             participates in the clinical trial.&#xD;
&#xD;
          -  Are &gt;18 years old.&#xD;
&#xD;
          -  Do not reject to participate.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CAP Cornellà de Llobregat (La Gavarra)</name>
      <address>
        <city>Cornellà De Llobregat</city>
        <state>Barcelona</state>
        <zip>08940</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Asistencia Primaria (CAP) Dr. Pujol i Capsada (CAP Pujol i Capsada)</name>
      <address>
        <city>El Prat de Llobregat</city>
        <state>Barcelona</state>
        <zip>08820</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAP Dr. Bartomeu Fabrés Anglada Gava 2</name>
      <address>
        <city>Gavà</city>
        <state>Barcelona</state>
        <zip>08850</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAP Florida Nord (CAP la Florida)</name>
      <address>
        <city>L'Hospitalet De Llobregat</city>
        <state>Barcelona</state>
        <zip>08905</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAP Florida Sud (CAP la Florida)</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08905</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 8, 2021</study_first_submitted>
  <study_first_submitted_qc>October 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2021</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fundació Sant Joan de Déu</investigator_affiliation>
    <investigator_full_name>Maria Rubio-Valera</investigator_full_name>
    <investigator_title>Head of Quality and Patient Safety</investigator_title>
  </responsible_party>
  <keyword>Pilot Study</keyword>
  <keyword>Feasibility Study</keyword>
  <keyword>Complex Intervention</keyword>
  <keyword>Real-World Data</keyword>
  <keyword>Cardiovascular Disease</keyword>
  <keyword>Diabetes Mellitus</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The research team is not the data owner as they are only re-using information that is the property of the public health institutions in Catalonia.&#xD;
Consequently, meta-data cannot be published by the authors nor data can be identified with a DOI.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

